Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Helius Medical Technologies ( (HSDT) ).
On July 7, 2025, Helius Medical Technologies filed an updated Prospectus Supplement to offer and sell up to $25 million of its common stock through Roth Capital Partners. The proceeds from this offering are intended for working capital and general corporate purposes, including commercialization efforts and research and development activities.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies faces significant financial and operational challenges, reflected in its poor financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further underscore the stock’s unattractiveness. Although the recent fundraising effort to meet Nasdaq compliance is a positive development, it does not substantially improve the company’s financial outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies, Inc. operates in the medical technology industry, focusing on the development and commercialization of products for neurological wellness and rehabilitation.
Average Trading Volume: 141,108
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.35M
For an in-depth examination of HSDT stock, go to TipRanks’ Overview page.